I
ImCheck Therapeutics
Biotech & Life Sciences · Marseille, France · Founded 2015
Designing and developing a new generation of immunotherapy antibodies MoreLess
ImCheck Therapeutics is at the forefront of developing next-generation immunotherapeutic antibodies, focusing on the modulation of the immune system through the butyrophilin BTN and BTN-like BTNL superfamily of checkpoint molecules. The company targets a broad spectrum of diseases, including cancer, infectious diseases, and autoimmune disorders. Operating within the biopharmaceutical sector, ImCheck leverages its proprietary knowledge to design innovative treatments that harness the body's immune response. The business model revolves around research and development, with revenue generation primarily through partnerships, licensing agreements, and potential future sales of approved therapies. ImCheck's clientele includes healthcare providers, research institutions, and potentially patients who benefit from advanced immunotherapy solutions. The company is actively involved in clinical trials, such as the Phase I/IIa EVICTION trial for ICT01, to validate the efficacy and safety of its therapeutic candidates. Keywords: immunotherapy, antibodies, cancer, infectious diseases, autoimmune, butyrophilin, checkpoint molecules, biopharmaceutical, clinical trials, immune modulation
Company overview
ImCheck Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Marseille, France
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 66.5
Valuation & funding
ImCheck Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2025 | $385M | $385M | Ipsen | ↗ |
| GRANTOther financing | Aug 2024 | $22M | — | France 2030 | ↗ |
| SERIES COther financing | Jun 2022 | $106M | $422M | Gimv · Eurazeo · The Leukemia & Lymphoma Society · Earlybird Venture Capital | ↗ |
| SERIES BOther financing | Sep 2020 | $6.6M | $264M | Pureos Bioventures | — |
| SERIES BOther financing | Dec 2019 | $53M | $211M | Alexandria Venture Investments · Agent Capital · Pfizer Ventures · Bpifrance | ↗ |
| GRANTOther financing | Aug 2019 | Bpifrance | — | ||
| EARLY VCOther financing | Oct 2017 | Bpifrance | ↗ | ||
| SERIES AOther financing | May 2017 | Gimv · Eurazeo · EQT Life Sciences · Boehringer Ingelheim Venture Fund | ↗ | ||
| SPINOUTOther financing | Jan 2015 | Aix-Marseille University · CNRS Innovation · French National Centre for Scientific Research - CNRS · INSERM | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$3.7M | — |
| 2025 | $0 | — | −$3.7M | — |
| 2024 | $0 | — | −$3.7M | — |
| 2023 | $0 | — | −$3.7M | — |
| 2022 | $0 | — | −$3.7M | — |
| 2021 | $0 | — | −$3.7M | — |
| 2020 | $0 | — | −$3.7M | — |
Growth signals
ImCheck Therapeutics website traffic
Latest recorded traffic for ImCheck Therapeutics is 1.3K monthly website visits, up 1200% over the last three months. ImCheck Therapeutics's team declined 16.1% over the past year.
Comparisons
ImCheck Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ImCheck Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
25 investors on ImCheck Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where ImCheck Therapeutics has talent and traffic
team presence
In the news
Latest news about ImCheck Therapeutics
Recent press, funding announcements, and product moves mentioning ImCheck Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about ImCheck Therapeutics
An AI-synthesized read of the highest-engagement posts about ImCheck Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImCheck Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.